$DRMA
Dermata Therapeutics Inc

2021 Q3 Form 10-Q Financial Statement

#000165495421010437 Filed on September 27, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $912.5K $462.8K $380.0K
YoY Change 117.47% 21.78%
% of Gross Profit
Research & Development $799.8K $867.2K $411.9K
YoY Change 563.9% 110.51%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $799.8K $867.2K $411.9K
YoY Change 563.9% 110.51%
Operating Profit -$1.712M -$1.330M -$792.8K
YoY Change 217.05% 67.76%
Interest Expense $651.00 $1.823K $28.86K
YoY Change -98.86% -93.68%
% of Operating Profit
Other Income/Expense, Net $1.330M $792.8K
YoY Change 67.76%
Pretax Income -$1.713M -$1.332M -$820.0K
YoY Change 186.73% 62.41%
Income Tax
% Of Pretax Income
Net Earnings -$1.713M -$1.332M -$821.6K
YoY Change 186.73% 62.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$205.7K -$159.9K -$1.58
COMMON SHARES
Basic Shares Outstanding 8.329M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.60M $427.2K
YoY Change
Cash & Equivalents $12.60M $427.2K
Short-Term Investments
Other Short-Term Assets $1.082M $709.7K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.69M $1.137M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $13.69M $1.137M
Total Long-Term Assets $0.00 $0.00
Total Assets $13.69M $1.137M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $769.9K $881.3K
YoY Change
Accrued Expenses $425.4K $586.5K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $174.8K
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $1.195M $1.643M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.195M $1.643M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.195M $1.643M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$33.43M -$31.72M
YoY Change
Common Stock $833.00 $191.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.49M -$505.8K -$2.203M
YoY Change
Total Liabilities & Shareholders Equity $13.69M $1.137M
YoY Change

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$1.713M -$1.332M -$821.6K
YoY Change 186.73% 62.09%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$2.210M -$903.2K -$740.0K
YoY Change -36.72% 22.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.39M 0.000 870.0K
YoY Change 538.3% -100.0%
NET CHANGE
Cash From Operating Activities -2.210M -903.2K -740.0K
Cash From Investing Activities
Cash From Financing Activities 14.39M 0.000 870.0K
Net Change In Cash 12.18M -903.2K 130.0K
YoY Change -1082.93% -794.78%
FREE CASH FLOW
Cash From Operating Activities -$2.210M -$903.2K -$740.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
586516 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
133477 USD
CY2021Q2 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
174844 USD
CY2020Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
1848495 USD
CY2021Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1140984 USD
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
556160 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1642666 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3783392 USD
CY2021Q2 us-gaap Liabilities
Liabilities
1642666 USD
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8328629 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
427202 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
530400 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
709662 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75053 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
1136864 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
605453 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2021Q2 us-gaap Assets
Assets
1136864 USD
CY2020Q4 us-gaap Assets
Assets
605453 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
881306 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
104276 USD
CY2020Q4 us-gaap Liabilities
Liabilities
3783392 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4390243 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1911009 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
191 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31203259 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31716498 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28079798 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-505802 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3177939 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1136864 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
605453 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
867197 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
411949 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1547785 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1373053 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
462772 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
380837 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2043957 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
768310 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1329969 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
792786 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3591742 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2141363 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1329969 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-792786 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3591742 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2141363 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
1823 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
28863 USD
us-gaap Interest Expense
InterestExpense
44958 USD
us-gaap Interest Expense
InterestExpense
101459 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1331792 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-821649 USD
us-gaap Net Income Loss
NetIncomeLoss
-3636700 USD
us-gaap Net Income Loss
NetIncomeLoss
-2242822 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.90
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1911009 shares
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1911009 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1911009 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1911009 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-210159 USD
CY2020Q1 drma Class B Common Units Issued Unaudited Amount
ClassBCommonUnitsIssuedUnauditedAmount
0 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1421173 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1631332 USD
CY2020Q2 drma Series1 C Preferred Units Issued Unaudited Amount
Series1CPreferredUnitsIssuedUnauditedAmount
250000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-821649 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-2202981 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3177939 USD
CY2021Q1 drma Series1 D Preferred Units Issued Unauduted Amount
Series1DPreferredUnitsIssuedUnaudutedAmount
5034801 USD
CY2021Q1 drma Conversion Of Common Units To Common Stock Unaudited Amount
ConversionOfCommonUnitsToCommonStockUnauditedAmount
0 USD
CY2021Q1 drma Conversion Of Preferred Units To Preferred Stock Unaudited Amount
ConversionOfPreferredUnitsToPreferredStockUnauditedAmount
0 USD
CY2021Q1 drma Conversion Of Warrant Units To Preferred Stock Warrants Unaudited Amount
ConversionOfWarrantUnitsToPreferredStockWarrantsUnauditedAmount
0 USD
CY2021Q1 drma Stock Based Compensation Unaudited
StockBasedCompensationUnaudited
1160049 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2304908 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
712003 USD
CY2021Q2 drma Stock Based Compensation Unaudited
StockBasedCompensationUnaudited
113987 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1331792 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-505802 USD
us-gaap Net Income Loss
NetIncomeLoss
-3636700 USD
us-gaap Net Income Loss
NetIncomeLoss
-2242822 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
322 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
322 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13970 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
72159 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1274036 USD
us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-634609 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
59668 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
777030 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10317 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
526840 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1966 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
1957267 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
119866 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1679433 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2122956 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-556482 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-115741 USD
us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
0 USD
us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
133592 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1562717 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
600000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
570000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
drma Net Proceeds From Issuance Of Series1 C Preferred Units
NetProceedsFromIssuanceOfSeries1CPreferredUnits
0 USD
drma Net Proceeds From Issuance Of Series1 C Preferred Units
NetProceedsFromIssuanceOfSeries1CPreferredUnits
250000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1576235 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
867851 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-103198 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1255105 USD
CY2020Q4 us-gaap Cash
Cash
530400 USD
CY2019Q4 us-gaap Cash
Cash
1991802 USD
CY2021Q2 us-gaap Cash
Cash
427202 USD
CY2020Q2 us-gaap Cash
Cash
736697 USD
us-gaap Interest Paid
InterestPaid
1420 USD
us-gaap Interest Paid
InterestPaid
29579 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1400 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1400 USD
drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
4464801 USD
drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
0 USD
drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
29936660 USD
drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
0 USD
CY2020Q2 drma Series1 A Preferred Units Shares
Series1APreferredUnitsShares
243897 shares
CY2020Q2 drma Series1 A Prerferred Warrant Units Shares
Series1APrerferredWarrantUnitsShares
70126 shares
CY2020Q2 drma Series1 B Preferred Units Shares
Series1BPreferredUnitsShares
317058 shares
CY2020Q2 drma Series1 Preferred Units Shares
Series1PreferredUnitsShares
336882 shares
CY2020Q2 drma Series1 C Preferred Units Shares
Series1CPreferredUnitsShares
2270866 shares
CY2020Q2 drma Class B Common Units Profits Interests
ClassBCommonUnitsProfitsInterests
362826 shares
CY2021Q2 drma Common Stock Options
CommonStockOptions
398199 shares
CY2021Q2 drma Common Stock Warrants
CommonStockWarrants
65303 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4601337 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3601655 shares
CY2021Q2 us-gaap Cash
Cash
427202 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31716498 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4028541 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1679433 USD
drma Reverse Stock Splitpolicytextblock
ReverseStockSplitpolicytextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses and estimated fair values of equity instruments. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
drma Patent Costs
PatentCosts
107354 USD
drma Patent Costs
PatentCosts
4258 USD
CY2021Q2 drma Patent Costs
PatentCosts
20099 USD
CY2020Q2 drma Patent Costs
PatentCosts
2472 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1547785 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1373053 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
867197 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
411949 USD
drma Schedule Of Potentially Dilutive Securities
ScheduleOfPotentiallyDilutiveSecurities
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"/><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>As of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series 1 Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336,882</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336,882</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series 1a Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">244,811</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">243,897</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series 1a Prerferred Warrant Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">69,212</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70,126</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series 1b Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">317,058</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">317,058</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series 1c Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,270,866</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,270,866</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series 1d Preferred Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">899,046</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Class B Common Units Profits Interests</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">362,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common Stock Options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">398,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common Stock Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">65,303</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total potentially dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,601,337</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,601,655</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q2 drma Series1 Preferred Units Shares
Series1PreferredUnitsShares
336882 shares
CY2021Q2 drma Series1 A Preferred Units Shares
Series1APreferredUnitsShares
244811 shares
CY2021Q2 drma Series1 A Prerferred Warrant Units Shares
Series1APrerferredWarrantUnitsShares
69212 shares
CY2021Q2 drma Series1 B Preferred Units Shares
Series1BPreferredUnitsShares
317058 shares
CY2021Q2 drma Series1 C Preferred Units Shares
Series1CPreferredUnitsShares
2270866 shares
CY2021Q2 drma Series1 D Preferred Shares
Series1DPreferredShares
899046 shares
CY2020Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
3000000 USD
CY2020Q4 us-gaap Notes Payable
NotesPayable
1145000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1730000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
125000 USD
CY2020Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.04 pure
CY2021Q1 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
10000000 USD
CY2021Q1 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.20 pure
CY2021Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1255000 USD
CY2021Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
311000 USD
CY2019Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
100000 USD
CY2021Q1 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
100000 USD
CY2021Q1 drma Preferred And Common Stock Par Value Per Share
PreferredAndCommonStockParValuePerShare
0.0001
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1648213 shares
drma Fair Market Value Option Percentage
FairMarketValueOptionPercentage
100
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1250000 shares
CY2021Q2 drma Estimated Fair Value Of Common Stock Price Per Share
EstimatedFairValueOfCommonStockPricePerShare
5.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.21 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
398199 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.83
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P9Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
398199 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.83
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
0 USD
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
0 USD
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
398199 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
209915 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
5.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y7M6D
us-gaap Schedule Of Repurchase Agreements
ScheduleOfRepurchaseAgreements
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>11. License Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">On March 31, 2017, the Company entered into a license agreement, as amended (“The License Agreement”) with Villani, Inc. (“Villani”) whereby Villani has granted the Company an exclusive, sub-licensable, royalty- bearing license (“The License”) under the Licensed Patents (as defined in the License Agreement), to formulate, develop, seek regulatory approval for, make or sell products that contain <em>Spongilla lacustris </em>(alone or in combination with other active or inactive ingredients) for the treatment of diseases, disorders and conditions of the skin, including but not limited to acne, rosacea, psoriasis, atopic dermatitis, seborrheic dermatitis, actinic keratosis and eczema that were developed using certain licensed know-how (“The Licensed Products”). The Company is responsible for the development (including manufacturing, packaging, non-clinical studies, clinical trials and obtaining regulatory approval and commercialization (including marketing, promotion, distribution, etc.)) for all Licensed Products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">In partial consideration of the License, the Company forgave a previous outstanding loan to Villani in the amount of $400,000. The License was amended in 2019 and, in consideration of the receipt of certain know-how and patents, the Company issued to Villani 5,221,156 Series 1c Preferred Units equal to 5% of the Company’s fully diluted capitalization, valued at $730,962. Pursuant to the License Agreement, the Company is required to make future milestone payments to Villani in an aggregate amount of up to $20.25 million upon the achievement of specified development and sales milestones, payable in cash or in equity, at the option of Villani. If the Company sublicenses the License, the Company is obligated to pay to Villani a sublicense fee of between 5% and 15% of Sublicense revenues (as defined in the License Agreement) received by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Pursuant to the License Agreement, the Company is required to make royalty payments to Villani in amounts equal to a single-digit percentage of net sales of Licensed Products and HMW Combination Products (as defined in the License Agreement), subject to certain adjustments as set forth in the License Agreement. Royalties shall be payable, on a country-by-country and Licensed Product-by Licensed Product basis, for the period of time from the effective date of the License Agreement until the later of (i) the expiration of the last to expire valid claim in such country (which is set to expire in 2023), (ii) the expiration of regulatory exclusivity for such Licensed Product in such country, and (iii) 15 years from the date of the first commercial sale of the Licensed Product in such country.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The License Agreement may be terminated (i) by either party for material breach with 90 days written notice, or 30 days’ notice if for material payment breach, if such material breach is not cured within such notice period, (ii) immediately upon written notice to either party if either party initiates a voluntary bankruptcy proceeding, dissolves or winds-up its business, (iii) immediately upon written notice to either party if either party becomes subject to involuntary bankruptcy proceedings, if such proceedings are not dismissed or stayed within 90 days. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The License agreement includes customary terms relating to, among others, indemnification, intellectual property protection, confidentiality, remedies and warranties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Refer to Note 14 - Subsequent Events for discussion of the Second Amendment to the License and Settlement Agreement.</p>
CY2020Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1145000 USD
us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
1255000 USD

Files In Submission

Name View Source Status
0001654954-21-010437-index-headers.html Edgar Link pending
0001654954-21-010437-index.html Edgar Link pending
0001654954-21-010437.txt Edgar Link pending
0001654954-21-010437-xbrl.zip Edgar Link pending
drma-20210630.xsd Edgar Link pending
drma-20210630_cal.xml Edgar Link unprocessable
drma-20210630_def.xml Edgar Link unprocessable
drma-20210630_lab.xml Edgar Link unprocessable
drma-20210630_pre.xml Edgar Link unprocessable
drma_10q.htm Edgar Link pending
drma_10q_htm.xml Edgar Link completed
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending